- Tryp Therapeutics Inc (OTCQB:TRYPF) announced that Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm for each one Tryp Share.
- The arm's length transaction will be completed by way of a statutory plan of arrangement under the Business Corporations Act.
- The purchase price of CAD$0.08 represents a 78% premium to the closing price of $0.045 and a 112% premium to the 20-day volume weighted price of $0.0378 per Tryp Share on December 8, 2023.
- Tryp shareholders expected to receive 4.52 Exopharm Shares for each one Tryp Share held, representing an aggregate transaction value of approximately $12.8 million.
- Source: Press Release
More on Tryp Therapeutics